Evidence map›Paper›PMID 27002765›Full record

ArticleCancer biomarkers : section A of Disease markers2016

MGMT hypermethylation and BCL-2 overexpression associated with superficial bladder cancer and recurrence.

Marzieh Jahed, Nader Ebadi, Mohamad Mivehchi, Tayebeh Majidizadeh, Majid Shahshanipour, Mojgan Asgari, Sara Ghadakzadeh, Seyed Ali Hosseini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in bladder cancer.International journal of clinical and experimental pathology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Marzieh JahedVaramin - Pishva Branch, Islamic Azad University, Varamin, Iran.
Nader EbadiVaramin - Pishva Branch, Islamic Azad University, Varamin, Iran.
Mohamad MivehchiVaramin - Pishva Branch, Islamic Azad University, Varamin, Iran.
Tayebeh MajidizadehDepartment of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Majid ShahshanipourDepartment of Urology, Hasheminejad Clinical Research Developing Center, Iran University of Medical Sciences, Tehran, Iran.
Mojgan AsgariDepartment of Pathology, Hasheminejad Clinical Research Developing Center, Iran University of Medical Sciences, Tehran, Iran.
Sara GhadakzadehDepartment of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Seyed Ali HosseiniDepartment of Genetic Disease, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Islamic Azad University of Varamin · IRHasheminejad Kidney Center · IRNational Institute of Genetic Engineering and Biotechnology · IRHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrinary bladder carcinoma is one of the leading causes of death among men, and its high recurrence rates make it one of the most solid tumors to treat. The silencing of the tumor suppressor gene by hypermethylation of the CpG islands and overexpression of proto-oncogene proteins are the main mechanisms in cancers. Here, we investigate methylation status of O6-methylguanine-DNA-methyltransferase (MGMT), a tumor suppressor gene and expression level of BCL-2 a proto-oncogene protein that is frequently observed in bladder carcinoma and its recurrences. MATERIALS AND

methodsWe analyzed the methylation of MGMT in 80 tissue samples of patients suffering from bladder cancer and 80 urine samples of cancer-free individuals by MS-PCR. Additionally, BCL-2 protein expression level was analyzed on these 80 tissue samples by immunohistochemistry.

results45% of patients had MGMT methylation, of which this hypermethylation does not have significant association with an increase in grade, but there was significant association in cases with recurrence tumors and metastasis tumors. Among patients with recurrence tumor, 92.5% patients showed MGMT hypermethylation; 66% of these showed BCL-2 overexpression.

conclusionOur data indicate that MGMT hypermethylation and BCL-2 overexpression may have an intense role in superficial bladder cancer recurrences.

Indexed as

DNA MethylationGene ExpressionAdultAgedAged, 80 and overCase-Control StudiesCpG IslandsDNA Modification MethylasesDNA Repair EnzymesFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingDNA Modification MethylasesDNA Repair EnzymesMAS1 protein, humanMGMT protein, humanProto-Oncogene MasProto-Oncogene Proteins c-bcl-2Tumor Suppressor ProteinsBCL-2Bladder cancermethylationMGMTtumor suppressor gene

Identifiers

PMID27002765
PMCPMC13016509
OpenAlexW2303017863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.